Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

PacBio, imec Sign Collaboration Deal

By Drug Discovery Trends Editor | July 30, 2012

Pacific Biosciences, provider of the PacBio RS high-resolution genetic analyzer, and Belgium-based nanoelectronics research center imec  announced a multi-year research collaboration focused on the development of advanced microchips for highly multiplexed single molecule genetic analysis.

This research and development project will build on Pacific Biosciences’ proprietary zero-mode waveguide (ZMW) technology and imec’s world-leading expertise in nanophotonics, CMOS sensors, technology integration and fabrication.

“From our inception we have been committed to exploiting the potential of the unique capabilities of our ZMW-based Single Molecule, Real-Time (SMRT) analysis technology to drive innovation in the life sciences,” said Michael Hunkapiller, President and Chief Executive Officer of Pacific Biosciences. “The goal of this collaboration is to harness the power of microchips to scale the capacity and throughput of our SMRT technology. We look forward to working with imec on this advanced development program as we continue to expand the application space for our platform.”

Luc Van den hove, President and Chief Executive Officer of imec, commented: “We are excited to work with the leading single molecule sequencing company to identify ways to bring greater economies of scale to this breakthrough technology through nanoscale semiconductor fabrication. This collaboration is another example of how imec leverages the research competencies of its life science program with its CMORE technology platforms to deliver full custom integrated nano/microsystem solutions to our partners for new and emerging markets.”

Date: July 27, 2012
Source: Pacific Biosciences

 


Filed Under: Drug Discovery

 

Related Articles Read More >

S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Drug companies sign “Most Favored Nation” deals, then raise prices anyway
New gonorrhea antibiotic could treat resistant infections
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE